Journal for ImmunoTherapy of Cancer (@jitcancer) / X

Journal for ImmunoTherapy of Cancer

7,086 posts

Journal for ImmunoTherapy of Cancer

@jitcancer

The official journal of @SITCancer, covering all aspects of tumor immunology and cancer immunotherapy. #JITC Editor-in-Chief: Michael T. Lotze, MD

Milwaukee, WI

Joined July 2019

Journal for ImmunoTherapy of Cancer
@jitcancer
Mar 31, 2023
New #JITC position article and guidelines: Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology bit.ly/3zFQgT3 @DrJNaidoo @JulieBrahmer @EladSharonMD @cappelliMD
35K
Journal for ImmunoTherapy of Cancer
@jitcancer
Oct 21, 2022
New #JITC review: Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages bit.ly/3VLTfmz @lea_paolini
Journal for ImmunoTherapy of Cancer
@jitcancer
Feb 1, 2024
New #JITC commentary: CARs are sharpening their weapons bit.ly/49fMlvJ
11K
Journal for ImmunoTherapy of Cancer
@jitcancer
Jan 25, 2022
New #JITC review: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies bit.ly/3tXz49L @peters_solange @lalaniMD
Journal for ImmunoTherapy of Cancer
@jitcancer
Nov 15, 2021
Does tumor burden impact tumor immunity and response to immunotherapy? Important review on this topic @NatRevClinOncol ow.ly/rFWA50GNIpz #JITC SM @MosheOrnsteinMD
Journal for ImmunoTherapy of Cancer
@jitcancer
Apr 9, 2022
Great talk from Yvonne Y. Chen on CAR-T vs CAR-NK at #AACR22. Check out this related #JITC review paper from Australia: Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies bit.ly/3DNeThE
Journal for ImmunoTherapy of Cancer
@jitcancer
Aug 3, 2023
New #JITC review: Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review bit.ly/47jNdzq
11K
Journal for ImmunoTherapy of Cancer
@jitcancer
Dec 22, 2022
New #JITC short report: Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma bit.ly/3PK8p9p @brian_rini @DrChoueiri @montypal
16K
Journal for ImmunoTherapy of Cancer
@jitcancer
Jan 20, 2025
New #JITC review: Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review bit.ly/40jqaCc @mcquadeMDLAc @MarcoRuella @CSpencerPhD @DrBetofMDPhD @BcellBruno
8.8K
Journal for ImmunoTherapy of Cancer
@jitcancer
Oct 4, 2022
New #JITC article: Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy bit.ly/3e0RKQl
Journal for ImmunoTherapy of Cancer
@jitcancer
Jun 8, 2023
New #JITC review: Vaccinating against cancer: getting to prime time bit.ly/3P0lP2t @gulleyj1 @lawfong
30K
Journal for ImmunoTherapy of Cancer
@jitcancer
Aug 22, 2023
New #JITC article: T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy bit.ly/45F6xFp @DrSapnaPatel @ANaingMD
32K
Journal for ImmunoTherapy of Cancer
@jitcancer
Dec 21, 2021
Meet JITC's New Deputy Editor-in-Chief: James L. Gulley, MD, PhD, FACP! Read more in the @sitcancer blog, The Sentinel bit.ly/3GYKAoA @gulleyj1
Journal for ImmunoTherapy of Cancer
@jitcancer
May 7, 2022
Important clinical implications of tumor-reactive CD8+ TIL in patients tumors. #AAI2022 More on TIL manipulation for cancer immunotherapy in @sitcancer #JITC 4-1BB co-stim enhances reinvigoration of CD39+ CD8 T cells from primary & mets in ovarian cancers jitc.bmj.com/content/8/2/e0…